21 CFR 864.7735
§ 864.7735 Prothrombin-proconvertin test and thrombotest.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 864.7735, § 864.7735 Prothrombin-proconvertin test and thrombotest, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/89388
- Permanent ID
ys:prov:89388@1- SHA-256
cccd1db4e2a53f6b881db4a1211d7b98a0a50a768960fbe49a8bef97f61a4c1b
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Identification. The prothrombin-proconvertin test and thrombotest are devices used in the regulation of coumarin therapy (administration of a coumarin anticoagulant such as sodium warfarin in the treatment of venous thrombosis and pulmonary embolism) and as a diagnostic test in conjunction with, or in place of, the Quick prothrombin time test to detect coagulation disorders.
(b) Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.